ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
최신 재무제표(Form-10K)에 따르면, ANI Pharmaceuticals Inc의 총 자산은 $0이며, 순손실입니다.
ANIP의 주요 재무 비율은 무엇인가요?
ANI Pharmaceuticals Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
ANI Pharmaceuticals Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
ANI Pharmaceuticals Inc 주요 수익원은 Rare Disease and Brands이며, 최신 수익 발표에서 수익은 483,933,000입니다. 지역별로는 United States이 ANI Pharmaceuticals Inc의 주요 시장이며, 수익은 852,443,000입니다.
ANI Pharmaceuticals Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 ANI Pharmaceuticals Inc의 순손실은 $0입니다.